Abliva: Pharming Group Announces Public Cash Offer to Acquire Abliva AB

Deal News | Dec 15, 2024 | Top Technology Ventures Ltd

Pharming Group N.V. has announced a public cash offer intending to acquire all issued and outstanding shares of Abliva AB. The deal is valued at approximately US$66.1 million and does not require external funding. This acquisition is a strategic move to strengthen Pharming's late-stage pipeline with Abliva's lead product, KL1333, currently in a pivotal clinical trial. The transaction reflects Pharming's aim to enhance its portfolio with a potential first-in-disease asset targeting mitochondrial DNA-driven primary mitochondrial diseases. Pharming Group plans to host a conference call to discuss further details about the acquisition.

Sectors

  • Pharmaceutical
  • Biotechnology

Geography

  • Sweden – Abliva AB, the target company of the acquisition, is based in Sweden.
  • Netherlands – Pharming Group N.V., the company making the acquisition offer, is based in the Netherlands.

Industry

  • Pharmaceutical – The article involves pharmaceutical companies focusing on drug development and clinical trials for mitochondrial diseases.
  • Biotechnology – The article includes companies working on biotechnological innovations such as Abliva's mitochondrial treatment.

Financials

  • $66.1 million – Total transaction value of Pharming's acquisition offer for Abliva.

Participants

NameRoleTypeDescription
Pharming Group N.V.Bidding CompanyCompanyPharming Group N.V. is a biopharmaceutical company making a public cash offer to acquire Abliva AB.
Abliva ABTarget CompanyCompanyAbliva AB is a biopharmaceutical company that is being acquired for its product KL1333.
Pharming Technologies B.V.Subsidiary of Pharming GroupCompanyPharming Technologies B.V. is the wholly-owned subsidiary through which Pharming is making the acquisition offer.